StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

Kyverna Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Kyverna Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$161.99M. For fiscal 2025 it was -$168.03M.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$168.03M–
FY2024Dec 31, 2024-$140.47M–
FY2023Dec 31, 2023-$60.70M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$42.80M–
Q2 FY2026Jun 30, 2026-$39.26M–
Q1 FY2026Mar 31, 2026-$41.02M–
Q4 FY2025Dec 31, 2025-$38.91M–
Q3 FY2025Sep 30, 2025-$38.43M–
Q2 FY2025Jun 30, 2025-$44.11M–
Q1 FY2025Mar 31, 2025-$46.91M–
Q4 FY2024Dec 31, 2024-$40.48M–
Q3 FY2024Sep 30, 2024-$38.47M–
Q2 FY2024Jun 30, 2024-$33.14M–
Q1 FY2024Mar 31, 2024-$28.88M–
Q4 FY2023Dec 31, 2023-$20.92M–
Q3 FY2023Sep 30, 2023-$16.08M–
Q2 FY2023Jun 30, 2023-$13.10M–
Q1 FY2023Mar 31, 2023-$11.05M–

More Kyverna Therapeutics figures

See a number that looks wrong?